Autologous Anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that are engineered to express a chimeric antigen receptor (CAR) composed of an anti-cluster of differentiation 19 (CD19) single chain variable fragment (scFv) linked to the intracellular signaling domains of 4-1BB (CD137) and the zeta chain of the TCR/CD3 complex (TCRzeta; CD247; CD3zeta), with potential immunomodulating and antineoplastic activities. Upon administration of the autologous anti-CD19 CAR-CD3zeta-4-1BB-expressing T-cells, these cells target, bind to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.

**Synonyms:** - Autologous CD19CAR-CD3zeta-4-1BB-expressing T-lymphocytes - Autologous CD3zeta-4-1BB-expressing CART-19 Cells